Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.055 CHF | -6.78% | -8.03% | +34.15% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
Business Summary
Number of employees: 28
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jeffrey Wager
CEO | Chief Executive Officer | 62 | 21-12-29 |
Martin Jakobovic
DFI | Director of Finance/CFO | - | - |
Stephan Wehselau
COO | Chief Operating Officer | 55 | 21-12-29 |
Chief Tech/Sci/R&D Officer | 68 | 21-12-29 | |
Muriel Fleming
HRO | Human Resources Officer | - | Nov. 30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Hartman
BRD | Director/Board Member | 62 | 21-12-29 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 21-12-29 |
Kuno Sommer
BRD | Director/Board Member | 68 | 12-08-31 |
Jeffrey Wager
CEO | Chief Executive Officer | 62 | 21-12-29 |
Robert Clarke
BRD | Director/Board Member | 56 | 21-12-29 |
Bernard Bollag
BRD | Director/Board Member | 63 | 13-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 67,664,495 | 31,538,191 ( 46.61 %) | 0 | 46.61 % |
Company contact information
Sector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+34.15% | 4.38M | |
-2.86% | 87.37B | |
+3.95% | 41.01B | |
-21.94% | 28.08B | |
+53.11% | 24.72B | |
-5.41% | 17.47B | |
-44.23% | 11.69B | |
-17.60% | 11.6B | |
-13.96% | 11.56B | |
-0.22% | 8.44B |
- Stock Market
- Equities
- POLN Stock
- Company Spexis AG